US 12,006,289 B2
Potassium channel inhibitors
David Tristram Brown, Glostrup (DK); Palle Christophersen, Glostrup (DK); Thomas Amos Jacobsen, Glostrup (DK); Janus S. Larsen, Glostrup (DK); Pernille Hartveit Poulsen, Glostrup (DK); and Dorte Strøbaek, Glostrup (DK)
Assigned to Saniona A/S, Glostrup (DK)
Appl. No. 17/437,447
Filed by Saniona A/S, Glostrup (DK)
PCT Filed Mar. 20, 2020, PCT No. PCT/EP2020/057816
§ 371(c)(1), (2) Date Sep. 9, 2021,
PCT Pub. No. WO2020/193419, PCT Pub. Date Oct. 1, 2020.
Claims priority of application No. 19164637 (EP), filed on Mar. 22, 2019.
Prior Publication US 2022/0169602 A1, Jun. 2, 2022
Int. Cl. C07D 205/04 (2006.01); C07C 211/40 (2006.01); C07C 233/62 (2006.01); C07C 271/24 (2006.01); C07C 311/07 (2006.01); C07D 207/09 (2006.01); C07D 213/61 (2006.01); C07D 265/30 (2006.01)
CPC C07D 205/04 (2013.01) [C07C 211/40 (2013.01); C07C 233/62 (2013.01); C07C 271/24 (2013.01); C07C 311/07 (2013.01); C07D 207/09 (2013.01); C07D 213/61 (2013.01); C07D 265/30 (2013.01)] 16 Claims
 
1. A compound of any of the following formulae:

OG Complex Work Unit Chemistry
wherein
R14 is selected from the group consisting of —C(O)—C1-8 linear or branched alkyl optionally substituted with cyclopropyl; —C(O)—O—C1-8 linear or branched alkyl optionally substituted with cyclopropyl; —C2-8 linear or branched alkyl optionally substituted with —OH; —H and —S(O)2—C1-8 linear or branched alkyl;
R3 is H or C1-5 linear or branched alkyl;
R4 is H, C1-5 linear or branched alkyl;
R6 is H or C1-5 linear or branched alkyl
R8 is selected from the group consisting of H, C1-5 linear or branched alkyl, and —C(O)—O—C1-8 linear or branched alkyl;
A is a phenyl or a pyridinyl, wherein the phenyl or pyridinyl is optionally substituted with one or more substituents R13 individually selected from the group consisting of halogen, —CX3, —OCX3, —CHX2, —OCHX2, —CH2CX3, and OCH2CX3; and
X is halogen;
or a pharmaceutically acceptable salt thereof.